Federal Register Final rule: FDA is amending the regulations to expand the scope of clinical investigator disqualification. When the FDA commissioner determines that an investigator is ineligible to receive one kind of test article (drugs, devices or new animal drugs), the investigator also will be ineligible to conduct any clinical investigation that supports an application for a research or marketing permit for other kinds of products regulated by FDA. This final rule is based in part upon recommendations from the Government Accountability Office. To view this final rule, click here.